Related Experiment Videos
Transcorneal oxygen therapy for glaucoma associated with sickle cell hyphema
1Delmarva Vitreoretinal Center, Salisbury, Maryland, USA. benner@shore.intercom.net
American Journal of Ophthalmology
|October 12, 2000
Summary
Transcorneal oxygen therapy effectively reduced intraocular pressure in three patients with sickle cell hyphema-induced glaucoma. This novel treatment showed rapid results without complications, warranting further investigation.
Area of Science:
- Ophthalmology
- Hematology
- Cellular Physiology
Background:
- Sickle cell hyphema can lead to secondary glaucoma due to increased intraocular pressure.
- Traditional treatments for this condition may have limitations.
- Transcorneal oxygen therapy presents a potential alternative approach.
Observation:
- Three patients with glaucoma secondary to sickle cell hyphema were treated.
- The treatment involved administering humidified oxygen transcorneally at 1-3 L/minute.
- Patient outcomes were monitored for intraocular pressure changes and complications.
Findings:
- All three patients experienced a significant reduction in intraocular pressure shortly after treatment.
- The transcorneal oxygen therapy was well-tolerated.
- No adverse events or complications were reported during the study.
Implications:
- Transcorneal oxygen therapy demonstrates promise in managing glaucoma associated with sickle cell hyphema.
- This approach may offer a safe and effective method for lowering intraocular pressure in affected individuals.
- Further clinical trials are recommended to validate these preliminary findings and explore the therapeutic potential of oxygen therapy in ophthalmology.